Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.31 +0.47%

+$0.11 today

Market cap
$876.61M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.47M

Average 0.33M

Returns on capital

Aktis Oncology, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

43.6%

avg 62.2%

ROIC

-31.8%

avg -23.2%

ROA

-24.1%

avg -18.5%

Analysis

ROE is currently the strongest return metric at 43.6% versus its period average of 62.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Matthew Roden

President, CEO & DirectorUSD 914.68K———

Akos Czibere

Chief Medical OfficerUSD 676.93K480<0.01%

Paul L. Feldman

Chief Scientific OfficerUSD 642.42K64——

Shulamit Ron-Bigger

Chief Operating OfficerUSD 536.71K450<0.01%

Patrick A. Baeuerle

Co-Founder & Member of Scientific Advisory Board—68——

Tyler Benedum

Chief Technical Officer—49——

Carlos Rodriguez

Executive Director of Corporate Development————

Kyle D. Kuvalanka

Chief Financial Officer—58——

Todd Foley

Co-Founder & Chairman—54——

Dasa Lipovsek

VP & Head of Lead Discovery————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

11

$3.23M

Net Transaction Value

−$3.23M

Net selling

Most Active

Czibere Akos

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 23, 26

Czibere Akos

Direct

Sell$103K
Sep 23, 26

Czibere Akos

Direct

Sell$155.6K
Jul 20, 26

Herrmann Ken

Direct

Sell$86.1K
Jul 20, 26

Herrmann Ken

Direct

Sell$33.2K
Jul 17, 26

Herrmann Ken

Direct

Sell$77.3K
Jul 8, 26

Ron-Bigger Shulamit

Direct

Sell$428.7K
Jul 8, 26

Ron-Bigger Shulamit

Direct

Sell$838.1K
Jul 8, 26

Ron-Bigger Shulamit

Direct

Sell$120.7K
Jul 8, 26

Czibere Akos

Direct

Sell$401.5K
Jul 8, 26

Czibere Akos

Direct

Sell$861.7K

1–10 of 11

Summary

Insiders reported 0 buys worth $0.00 and 11 sells worth $3.23M over the last 12 months. That adds up to net selling of $3.23M. Czibere Akos was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
+70.9% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +70.9% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Aktis Oncology, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AKTS's management, answered from reported figures.

Who manages AKTS?

Aktis Oncology, Inc. (AKTS) lists 10 active executives. The top listed executive is Akos Czibere, Chief Medical Officer.

Are AKTS insiders buying or selling?

Recent insider activity shows net selling of $3.23M.